Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
204.00
-1.04 (-0.51%)
At close: Dec 5, 2025, 4:00 PM EST
203.05
-0.95 (-0.47%)
After-hours: Dec 5, 2025, 7:51 PM EST
Insmed Revenue
Insmed had revenue of $142.34M in the quarter ending September 30, 2025, with 52.36% growth. This brings the company's revenue in the last twelve months to $447.02M, up 30.34% year-over-year. In the year 2024, Insmed had annual revenue of $363.71M with 19.17% growth.
Revenue (ttm)
$447.02M
Revenue Growth
+30.34%
P/S Ratio
86.87
Revenue / Employee
$351,709
Employees
1,271
Market Cap
43.51B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 363.71M | 58.50M | 19.17% |
| Dec 31, 2023 | 305.21M | 59.85M | 24.39% |
| Dec 31, 2022 | 245.36M | 56.90M | 30.19% |
| Dec 31, 2021 | 188.46M | 24.05M | 14.63% |
| Dec 31, 2020 | 164.41M | 27.95M | 20.48% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
INSM News
- 2 days ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 4 days ago - Insmed Incorporated (INSM) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha
- 6 days ago - 30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - The Motley Fool
- 16 days ago - These 15 stocks are still showing momentum — and a market-beating edge - Market Watch
- 18 days ago - European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union - PRNewsWire
- 18 days ago - Insmed Incorporated (INSM) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 23 days ago - Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good - PRNewsWire
- 4 weeks ago - Artisan Global Opportunities Fund Q3 2025 Portfolio Update - Seeking Alpha